Skip to Content

Johnson & Johnson

JNJ: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$512.00QgxwCpwvmmnm

Johnson & Johnson Earnings: Broad Portfolio Strength Drives Solid Results

Johnson & Johnson reported stronger second-quarter results than we had projected and raised 2023 guidance, but we don't expect any major changes to the firm's fair value estimate based on the slight outperformance.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of JNJ so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center